Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role

FOR IMMEDIATE RELEASE Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role Fairfax, VA — May 12, 2026 — Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first-in-class targeted oral therapy for patients […]

Investigational Inhibitor of Active RAS Shows Clinical Promise – Alexander I. Spira, MD, PhD, FACP

Investigational Inhibitor of Active RAS Shows Clinical Promise –  The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C